S. Korea eyes chip alliance with Netherlands
Suneung without 'killer questions' still not easy, results show
US defense policy bill calls for maintaining 28,500 US troops in Korea
Teens' excessive smartphone use linked to mental health risk: study
SK carries out complete reshuffle of top brass
S. Korea, US, Japan to discuss regional security issues: White House
Ruling party reform committee disbands early, says job half done
Ex-justice minister's daughter attends forgery trial in college admissions scandal
Auditor says Moon govt distorted 2020 death of fisheries official
Moon officials tried to cover up North Korea’s murder of South Korean: state inspectors
SK Inc.’s French bio arm sets to facility expansionBy Bae Hyunjung
Published : June 14, 2021 - 14:45
The French company has announced the launch of project SKY, a plan to inject some 58 million euros ($70 million) in the construction of its new manufacturing plant. Slated for completion by 2023, the forthcoming facility will be one of the largest advanced therapy medicinal product, or ATMP, facilities in Europe.
The new building will house two additional production lines with several 1,000 liter-scale bioreactors, as well as a centralized warehouse, production and storage sites, and quality control lab resources, officials said.
Leading the project as key contractors will be CBI, a subsidiary of Vinci Construction France, and Pharmaplan, an engineering service for the pharmaceutical industry.
With the latest investment, Yposkesi and SK Inc. seek to address the shortage in the capacity shortage in the bio sector, especially in carrying out clinical tests and commercializing new therapeutic drugs, according to Lee Dong-hoon, executive vice president of SK Inc.
“SKY is the culmination of our industrial strategy, guaranteeing clients a range of quality services from early clinical drug development through all phases to the manufacture of large-scale commercial batches of ATMPs,” said Alain Lamproye, executive chairman of Yposkesi.
“This project will also showcase our outstanding technological know-how in bioproduction for gene therapy drugs.”
In March this year, SK Inc., the holding unit and investment firm of South Korea’s third-largest conglomerate SK Group, acquired a 70 percent stake in Yposkesi, a France-based contract development and manufacturing organization, or CDMO, that specializes in cell and gene therapies.
The given deal marked the company’s third acquisition in the global CMO business, following the acquisition of Bristol Myers Squibb in 2017 and AMPAC in 2018.
By Bae Hyun-jung (firstname.lastname@example.org)
4 contentious bills scrapped in revote after Yoon's veto
S. Korea logs current account surplus for 6th month in October
Ex-Democratic Party chair denies bribery, illegal campaign allegations